Eupraxia Pharmaceuticals Inc. (EPRX) on Tuesday reported positive 36-week data from the highest dose cohort in its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis.
In the highest dose cohort, EoEHSS Stage and Grade scores were reduced by 0.59 and 0.53, representing declines of 90% and 88%, respectively, indicating improvements across both inflammatory and structural components of the disease.
Peak Eosinophil Count fell 72% from baseline at week 36, marking the largest reduction observed across all dose cohorts.
The company said EP-104GI continued to be well tolerated, with no drug-related serious adverse events reported among 31 patients treated and more than 230 patient-months of follow-up.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.